Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Daniel Faga is President, CEO at First Tracks Biotherapeutics. OQRO lists 1 transaction filed with the SEC under this name, the latest on Nov 3, 2026, each linked to the official Form 4.
President, CEO
Disclosures on record
1
Companies involved
1
Daniel Faga has no open-market purchase on record since 2024. Sales in 1 of the 3 years since 2024.
Daniel Faga reported 0 open-market purchases and 3 sales since 2024; no open-market purchase.
| Year | Bought | Sold |
|---|---|---|
| 2024 | — | $3.54M3×3 trades |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Daniel Faga reported 0 open-market purchases and 3 sales here, 2024.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.
First Tracks BiotherapeuticsTRAX
Nov 1, 2026136Kdisclosed Nov 3
DetailsOfficial recordDaniel Faga has no open-market purchase on record since 2024. Sales in 1 of the 3 years since 2024.
In SEC filings since 2024: no open-market purchase is on record; the latest open-market sale is from 2024.
Anaptysbio (ANAB), from 2024 to 2024: 0 purchases and 3 sales.